|
|
T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor
|
|
|
T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally
|
|
|
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
|
|
|
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
|
|
|
T2 Biosystems Announces Third Quarter 2024 Financial Results
|
|
|
T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024
|
|
|
T2 Biosystems to Host Business Update Call on October 10, 2024
|
|
|
T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform
|
|
|
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
|
|
|
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
|
